Quantcast

Latest Actavis Stories

2014-02-18 16:26:50

DUBLIN, Feb. 18, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to issue its fourth quarter and full-year 2013 earnings release as planned on Thursday, February 20, 2014, prior to the opening of the U.S. markets. However, following the Company's announcement earlier today regarding its proposed acquisition of Forest Laboratories, Inc., Actavis has elected not to conduct an earnings conference call to discuss the quarterly and full-year results. The...

2014-02-18 08:30:08

- Creates an Innovative New Model in Specialty Pharmaceuticals Leadership, with $15 Billion in Revenue and a Growing ~$7 Billion North American Specialty Brand Business - DUBLIN, Ireland and NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest...

2014-02-11 08:32:16

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) announced today that it intends to release fourth quarter 2013 financial results on Thursday, February 20, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 20, 2014 to discuss its financial results. The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573, and the Conference ID...

2014-02-04 08:34:45

DUBLIN, Feb. 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. Actavis' ANDA product is a generic version of Cephalon's Treanda(®), a treatment for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Cephalon, Inc. filed suit against Actavis on January 31,...

2014-01-31 08:24:59

- 2014 Revenue forecast to be $10+ Billion - DUBLIN, Jan. 31, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today provided a detailed look into the company's newly restructured global commercial operations, expanded pipeline and outlook for continued long-term growth during its fifth annual Investor Meeting in New York. In conjunction with the meeting, the Company reiterated that it expects 2013 non-GAAP earnings per diluted share to be...

2014-01-31 08:24:53

- Realigns Existing Executive Team Expertise - DUBLIN, Jan. 31, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced a realignment of its global strategic business structure to maximize the Company's newly strengthened position as a leading specialty pharmaceutical developer, manufacturer and marketer, and to enhance Actavis' position for continued long-term growth. Under the new organizational structure, announced at Actavis' 2014 Investor Meeting in New York, Actavis' global...

2014-01-24 16:22:14

DUBLIN, Jan. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co., Ltd to acquire Actavis' interest in Actavis (Foshan) Pharmaceuticals Co., Ltd., an Actavis subsidiary based in Foshan, China. Actavis intends to continue further commercial operations in China in collaboration with its preferred business partners. "Actavis is focused on strengthening our investment in high-growth...

2014-01-22 12:27:07

DUBLIN, Jan. 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that its subsidiary, Watson Laboratories, Inc., has submitted an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Allergan, Inc.'s Restasis(®) (cyclosporine ophthalmic emulsion) 0.05% product. Actavis' ANDA was submitted prior to the issuance of FDA guidance related to approval of generic versions of Restasis(®)...

2014-01-18 00:20:27

DUBLIN, Jan. 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to enter into an agreement for Aurobindo Pharma Limited (BSE: 524804) to acquire Actavis' generics commercial operations in seven markets in Western Europe. The transaction is conditional on certain antitrust approvals and completion of employee consultation processes. Aurobindo would acquire Actavis' pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium,...

2014-01-17 20:22:00

DUBLIN, Jan. 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin(®) Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'